Bank of America Securities has downgraded The Cooper Companies, sending a clear signal that the contact lens maker's latest stumble is more than a blip. The bank also slashed its price target on the stock to $65, down from a previous level, after CooperVision—the company's contact lens division—reset its growth expectations for the second time this fiscal year.
CooperVision now expects sales growth of just 1% to 2%, a sharp cut from the 3.5% to 4.5% it had previously guided. The downgrade follows a 2% decline in sales during the company's fiscal third quarter, a miss that caught many investors off guard.
Why the outlook keeps slipping
According to Bank of America, much of the problem lies in the United States, where customers have been running down excess inventory rather than placing new orders. This "destocking" is a temporary slowdown, the bank argues, and it expects the drag to fade by the fiscal fourth quarter. The wider contact lens market, it notes, continues to grow—suggesting the issue is more about timing than a loss of demand.
Still, this is the second reset for CooperVision this year, and that pattern is hard to ignore. For a company that had been seen as a steady grower in the eye care space, repeated guidance cuts can shake investor confidence, even if the underlying market remains healthy.
CooperSurgical: a limited exit path
Bank of America also flagged a separate concern: Cooper's options for selling its CooperSurgical unit appear limited. CooperSurgical, which makes medical devices and fertility products, has been seen by some investors as a potential divestiture candidate—a way to unlock value or raise cash. But the bank's note suggests that a sale may not be easy, which could weigh on the stock's valuation.
For everyday investors, this matters because it narrows the list of catalysts that could lift the share price. When a company's core business is slowing and a potential asset sale looks difficult, the stock often has fewer reasons to rally.
What it means for investors
This downgrade is a reminder that even well-regarded companies can hit rough patches. For those who hold Cooper shares, the key question is whether the inventory issue really is temporary. If Bank of America is right, the fiscal fourth quarter could show a rebound, and the stock might recover. If not, further cuts could follow.
It's also worth noting that this is not the first time Bank of America has adjusted a price target this week. The bank recently downgraded Crescent Capital over lingering loan issues, and it also raised its target on Legrand while keeping an underperform rating. That shows the bank is actively reassessing a range of names, not just Cooper.
For those watching the broader market, the contact lens industry is a niche but steady part of the healthcare sector. Cooper's struggles come at a time when oil prices are stoking inflation fears globally, which could affect consumer spending on discretionary items like premium contact lenses. However, contact lenses are often considered a necessity for many users, which may cushion the blow.
Investors should also keep an eye on how Cooper's management responds. The company recently beat earnings but trimmed its outlook and boosted its buyback to $3 billion, a move that can support the stock price even when fundamentals weaken. Buybacks can be a sign that management believes the shares are undervalued, but they don't fix operational issues.
The bottom line
Bank of America's downgrade and $65 price target reflect a more cautious view of Cooper's near-term prospects. The inventory destocking is a real headwind, but it may be temporary. The bigger question is whether CooperVision can regain its growth momentum and whether CooperSurgical can be monetized. For now, the market seems to be taking a wait-and-see approach.
As always, this is not a recommendation to buy or sell. It's a snapshot of what one major bank thinks, and it's worth weighing alongside other information before making any investment decisions.
